

# Ophthalmic Drugs Market Set to Surge to \$58.13 Billion by 2027 at a 5.6% CAGR

*The global ophthalmic drugs market was valued at \$36,488.48 million in 2019 and is expected to reach \$58,134.92 million by 2027, growing at a CAGR of 5.6%.*

WILMINGTON, DE, UNITED STATES, February 5, 2025 /EINPresswire.com/ --

The global [ophthalmic drugs market](#) has witnessed significant growth in recent years, driven by an aging population and a rise in eye-related disorders. In 2019, the market was valued at approximately \$36.49 billion and is projected to reach \$58.13 billion by 2027, reflecting a CAGR of 5.6% from 2020 to 2027.



Get Sample PDF Copy Here: <https://www.alliedmarketresearch.com/request-sample/310>

## Ophthalmic Drugs Market Key Growth Factors

Several factors contribute to the expansion of the ophthalmic drugs market:

- 1. Aging Population:** The increase in the elderly population has led to a higher prevalence of age-related eye conditions such as cataracts, glaucoma, and macular degeneration. This demographic shift has escalated the demand for effective ophthalmic treatments.
- 2. Prevalence of Eye Diseases:** There is a notable rise in eye diseases globally, including diabetic retinopathy and age-related macular degeneration (AMD). The growing incidence of diabetes has further contributed to the surge in diabetic retinopathy cases, necessitating advanced ophthalmic drugs.
- 3. Advancements in Drug Development:** Continuous research and development efforts have led to the introduction of innovative ophthalmic drugs and drug delivery systems, enhancing treatment efficacy and patient compliance.
- 4. Government Initiatives:** Various government programs aimed at preventing blindness and promoting eye health have increased awareness and accessibility to ophthalmic treatments,

thereby propelling market growth.

Have Any Query? Ask Our Experts: <https://www.alliedmarketresearch.com/purchase-enquiry/310>

## Ophthalmic Drugs Market Segmentation

The ophthalmic drugs market is segmented based on indication, type, dosage form, distribution channel, and therapeutic class.

### • By Indication:

- Retinal Disorders: This segment includes treatments for conditions like wet and dry age-related macular degeneration and diabetic retinopathy.
- Glaucoma: Medications aimed at reducing intraocular pressure to prevent optic nerve damage.
- Dry Eye: Therapies designed to alleviate symptoms of dry eye syndrome.
- Infection/Inflammation/Allergy: Drugs targeting various ocular infections, inflammations, and allergic reactions.
- Others: Includes treatments for less common eye conditions.

### • By Type:

- Prescription Drugs: Medications that require a doctor's prescription for use.
- Over-the-Counter (OTC) Drugs: Medications available without a prescription.

### • By Dosage Form:

- Liquid Ophthalmic Drug Forms: Includes eye drops and solutions, which are commonly used due to their ease of application.
- Solid Ophthalmic Drug Forms: Such as inserts and implants that provide sustained drug release.
- Semi-Solid Ophthalmic Drug Forms: Includes ointments and gels that offer longer contact time with the ocular surface.
- Multicompartment Drug Delivery Systems: Advanced systems designed for targeted and controlled drug delivery.
- Other Ophthalmic Drug Forms: Encompasses emerging drug delivery technologies.

### • By Distribution Channel:

- Hospital Pharmacies: Pharmacies located within hospitals dispensing ophthalmic medications.
- Drug Stores: Retail outlets providing a range of pharmaceutical products, including eye care drugs.
- Online Pharmacies: Digital platforms offering the convenience of purchasing medications online.

□ Others: Includes clinics and specialized eye care centers.

• By Therapeutic Class:

□ Anti-Glaucoma: Drugs that help lower intraocular pressure.

□ Anti-Infection: Medications used to treat bacterial, viral, or fungal eye infections.

□ Anti-Inflammation: Drugs aimed at reducing ocular inflammation.

□ Anti-Allergy: Medications that alleviate allergic reactions affecting the eyes.

□ Others: Includes various other therapeutic categories addressing different eye conditions.

### Key Players in the Ophthalmic Drugs Market

The ophthalmic drugs market features several prominent companies driving innovation and competition. Notable key players include:

- AbbVie Inc. (Allergan plc)
- Alcon Inc.
- Bausch & Lomb Incorporated
- F. Hoffmann-La Roche Ltd (Genentech, Inc.)
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Santen Pharmaceutical Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd. (Actavis Generics)

These companies are at the forefront of developing and marketing ophthalmic drugs, contributing significantly to the market's growth and the advancement of eye care treatments.

The ophthalmic drugs market is poised for substantial growth, driven by demographic trends, increasing prevalence of eye diseases, and continuous advancements in pharmaceutical research. Strategic initiatives by key industry players further bolster the market's expansion, promising improved treatment options for patients worldwide.

Procure Complete Report Here: <https://www.alliedmarketresearch.com/checkout-final/18421e43be74aea759e86c86be0988b4>

Thanks for reading this article; you can also get an individual chapter-wise sections or region-wise report versions like North America, LATAM, Europe, or Southeast Asia.

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of

Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa

Allied Market Research

+ + 1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[YouTube](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/783358488>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.